宫颈托与阴道黄体酮用于双胎及以上妊娠伴宫颈缩短女性的比较:一项随机对照试验
在荷兰20家医院开展开放标签、优效性、多中心随机对照试验,比较宫颈托与阴道黄体酮对多胎妊娠伴无症状宫颈长度<38 mm女性的效果;因中期分析无效而提前终止,共随机276例。两组复合不良围产结局及自发性早产率无显著差异,但在未产女性中宫颈托组复合结局更常见。
要点
- 多胎妊娠伴宫颈长度<38 mm女性中,宫颈托与阴道黄体酮200 mg/日的复合不良围产结局无显著差异。
- 未产女性中宫颈托组复合不良围产结局发生率高于黄体酮组(RR 1.88,95%CI 1.03–3.43)。
- 宫颈长度≤25 mm亚组两组复合围产结局无显著差异。
核心结论
- 在多胎妊娠且孕中期宫颈长度<38 mm的女性中,未发现宫颈托在预防围产期并发症方面优于阴道黄体酮。
- 黄体酮可能具有适度效果,未来研究应关注多胎妊娠的其他干预措施如宫颈环扎术,包括超声和体格检查指示的环扎。
研究设计与样本
- 开放标签、优效性、多中心随机对照试验,在荷兰20家医院开展。
- 纳入健康多胎妊娠、孕16至22周无症状宫颈长度<38 mm的女性,目标样本量332例。
- 因中期分析无效而提前终止,共随机276例多胎妊娠(含7例三胎妊娠),1:1分配至宫颈托组(N=138)或阴道黄体酮200 mg/日组(N=138),治疗至孕36周或更早如有指征。
- 主要结局为复合不良围产结局,次要结局包括孕24、28、32、34和37周前自发性早产率;基于宫颈长度、产次、绒毛膜性和胎儿数进行预设亚组分析。
主要发现
- 在531例新生儿(宫颈托组N=269,黄体酮组N=262)中,复合不良围产结局发生率宫颈托组19.7% vs 黄体酮组13.7%(粗RR 1.43;95%CI 0.85–2.4,p=0.18)。
- 两组自发性早产率无显著差异。
- 宫颈长度≤25 mm亚组中,复合围产结局无显著差异(41.1% vs 34.7%,RR 1.18;95%CI 0.60–2.33,交互作用p=0.63)。
- 未产女性中,宫颈托组复合结局较黄体酮组更常见(30.0% vs 15.9%,RR 1.88;95%CI 1.03–3.43,交互作用p=0.93)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究主要局限性包括无法对干预措施设盲,可能引入偏倚。
- 黄体酮组自报服药依从性低,可能导致依从性高估和符合方案分析中黄体酮预防潜力被低估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In absence of direct comparisons, consensus on the preferred preventive treatment for multiple pregnancies with a short cervix is lacking. Therefore, we compared the effectiveness of a cervical pessary and vaginal progesterone in the prevention of adverse perinatal outcomes and preterm birth (PTB) in women with a multiple pregnancy, no prior spontaneous PTB (sPTB) before 34 weeks' gestation, and an asymptomatic mid-trimester shortened cervix below 38 mm. METHODS AND FINDINGS: This open-label, superiority, multi-centre randomised controlled trial was conducted in 20 hospitals in the Netherlands. Women with a healthy multiple pregnancy and an asymptomatic cervical length (CL) below 38 mm between 16 and 22 weeks' gestation were eligible, with a target sample size of 332. Following an interim analysis, the study was halted for futility. A total of 276 multiples, including seven triplet pregnancies, were randomised 1:1 to receive either an Arabin cervical pessary (N = 138) or vaginal progesterone 200 mg daily (N = 138) until 36 weeks' gestation or earlier if indicated. The primary outcome was a composite adverse perinatal outcome, with secondary outcomes including rates of (s)PTB before 24, 28, 32, 34, and 37 weeks. Predefined subgroup analyses were conducted based on CL, parity, chorionicity, and number of foetuses. Among 531 neonates (pessary N = 269, progesterone N = 262), the composite adverse perinatal outcome occurred in 19.7% of neonates in the pessary group versus 13.7% in the progesterone group (crude RR 1.43; 95% CI [0.85,2.4], p = 0.18). The rates of (s)PTB were not significantly different between groups. In the subgroup with a CL of ≤25 mm, no significant difference in the composite perinatal outcome was found (41.1% versus 34.7%, RR 1.18; 95% CI [0.60,2.33], interaction p = 0.63). However, among nulliparous women, the composite outcome was more frequent in the pessary group compared to progesterone (30.0% versus 15.9%, RR 1.88; 95% CI [1.03,3.43], interaction p = 0.93). The study's main limitations include the inability to blind interventions, potentially introducing bias, and low self-reported medication compliance in the progesterone group, which may have led to overestimated adherence and underestimated progesterone's preventive potential in the per-protocol analysis. CONCLUSION: In women with multiple pregnancies and a midtrimester short cervix below 38 mm, we found no superiority of a cervical pessary compared to vaginal progesterone the prevention of perinatal complications. While progesterone may have a modest effect, future studies should focus on other interventions in multiple pregnancies such as a cerclage, both ultrasound- and physical examination-indicated. TRIAL REGISTRATION: This trial was registered at the International Clinical Trial Registry Platform (ICTRP, EUCTR2013-002884-24-NL, https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2013-002884-24-NL).
引用
- van Dijk CE, van Gils AL, van Zijl MD, et al. Cervical pessary versus vaginal progesterone in women with a multiple pregnancy and a short cervix: A randomised controlled trial. PLoS Med. 2025. PMID: 41183078. doi:10.1371/journal.pmed.1004586
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。